{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:20:34Z","timestamp":1788970834170,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","cysticfibrosisjournal.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jcf.2024.08.005","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T01:03:38Z","timestamp":1724979818000},"page":"40-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Glucagon-like-peptide-1 agonist therapy in adults with cystic fibrosis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0585-0281","authenticated-orcid":false,"given":"Sanghoon","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2407-7374","authenticated-orcid":false,"given":"Raksha","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4251-5737","authenticated-orcid":false,"given":"Sasan","family":"Mirfakhraee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jcf.2024.08.005_bib0001","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/dc09-0586","article-title":"Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.jcf.2024.08.005_bib0002","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American diabetes association and a clinical practice guideline of the cystic fibrosis foundation, endorsed by the pediatric endocrine society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.jcf.2024.08.005_bib0003","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcf.2022.03.010","article-title":"Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2024.08.005_bib0004","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","article-title":"Glucagon-like peptide 1 in health and disease","volume":"14","author":"Andersen","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"1\u20132","key":"10.1016\/j.jcf.2024.08.005_bib0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","article-title":"GIP and GLP-1, the two incretin hormones: similarities and differences","volume":"1","author":"Seino","year":"2010","journal-title":"J Diabetes Investig"},{"issue":"2","key":"10.1016\/j.jcf.2024.08.005_bib0006","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jcf.2024.08.005_bib0007","doi-asserted-by":"crossref","DOI":"10.1177\/2042018821997320","article-title":"GLP-1 receptor agonists: an updated review of head-to-head clinical studies","volume":"12","author":"Trujillo","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.jcf.2024.08.005_bib0008","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jcf.2024.08.005_bib0009","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Frias","year":"2021","journal-title":"N Engl J Med"},{"issue":"3\u20134","key":"10.1016\/j.jcf.2024.08.005_bib0010","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev Diabet Stud"},{"issue":"7","key":"10.1016\/j.jcf.2024.08.005_bib0011","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa167","article-title":"Semaglutide in cystic fibrosis-related diabetes","volume":"105","author":"Gnanapragasam","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.jcf.2024.08.005_bib0012","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/dom.13544","article-title":"Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: a randomized crossover trial","volume":"21","author":"Geyer","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.jcf.2024.08.005_bib0013","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3945\/ajcn.112.051409","article-title":"Longitudinal trends in nutritional status and the relation between lung function and BMI in cystic fibrosis: a population-based cohort study","volume":"97","author":"Stephenson","year":"2013","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"10.1016\/j.jcf.2024.08.005_bib0014","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jcf.2021.12.014","article-title":"Nutritional status and lung function in children with pancreatic-sufficient cystic fibrosis","volume":"21","author":"Madde","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2024.08.005_bib0015","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.rmed.2005.09.021","article-title":"The effect of massive weight loss on pulmonary function of morbid obese patients","volume":"100","author":"Santana","year":"2006","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.jcf.2024.08.005_bib0016","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2967\/jnumed.106.038679","article-title":"GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting","volume":"48","author":"Korner","year":"2007","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.jcf.2024.08.005_bib0017","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1210\/en.2013-1666","article-title":"Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice","volume":"154","author":"Viby","year":"2013","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.jcf.2024.08.005_bib0018","first-page":"S111","article-title":"American diabetes association professional practice C. 6. Glycemic goals and hypoglycemia: standards of care in diabetes-2024","volume":"47","author":"Anon","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcf.2024.08.005_bib0019","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.jcf.2019.08.004","article-title":"Hypoglycemia in cystic fibrosis: prevalence, impact and treatment","volume":"18","author":"Moheet","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2024.08.005_bib0020","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/00325481.2021.2002616","article-title":"Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice","volume":"134","author":"Wharton","year":"2022","journal-title":"Postgrad Med"},{"issue":"4","key":"10.1016\/j.jcf.2024.08.005_bib0021","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jcf.2021.05.016","article-title":"Review of gastrointestinal motility in cystic fibrosis","volume":"20","author":"Henen","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2024.08.005_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Martinez","year":"2022","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.jcf.2024.08.005_bib0023","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.diabet.2017.05.009","article-title":"Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy","volume":"43","author":"Nakatani","year":"2017","journal-title":"Diabetes Metab"},{"issue":"2","key":"10.1016\/j.jcf.2024.08.005_bib0024","doi-asserted-by":"crossref","first-page":"e13731","DOI":"10.1111\/ijcp.13731","article-title":"Switching between GLP-1 receptor agonists in clinical practice: expert consensus and practical guidance","volume":"75","author":"Jain","year":"2021","journal-title":"Int J Clin Pract"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324008312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324008312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T17:11:14Z","timestamp":1738257074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324008312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1569199324008312"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.08.005","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like-peptide-1 agonist therapy in adults with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}